ZLNA — Zelluna ASA Share News
0.000.00%
Last trade - 00:00- NOK544.15m
- NOK451.38m
Brief: Ultimovacs Q4 Total Loss At NOK 55.9 Mln
Brief: Ultimovacs Sees Topline Results From UV1 Phase II Trial INITIUM In March
Brief: Ultimovacs Completes Exploratory Phase I TENDU Study Of TET Vaccine Technology Platform
Brief: Ultimovacs Q3 Oper Profit At NOK 54.7 Mln
Brief: Ultimovacs Announces Protocol Amendment In UV1 Phase II Study Initium In Malignant Melanoma
Brief: Ultimovacs Provides Phase II NIPU Results
Brief: Ultimovacs Announces NIPU Results Presented At ESMO 2023
Brief: Ultimovacs Gets FDA Orphan Drug Designation For UV1 Cancer Vaccine
Brief: Ultimovacs Expects Current Cash Resources To Support Ops To H2 2024
Brief: Ultimovacs Q2 Operating Expenses at NOK 50.6 Million
Brief: Ultimovacs Announces Results Of UV1-103 Phase I Trial
Brief: Ultimovacs Provides Update From Phase I Study In Malignant Melanoma
Brief: Ultimovacs ASA Provides Update On Phase 2 NIPU Trial Evaluating UV1 In Second-Line Patients With Malignant Pleural Mesothelioma
Brief: Ultimovacs Q1 Operating Expenses at NOK 50.8 Million
Brief: Ultimovacs Updates On Timeline For Readout Of Initium Study Of UV1 In Malignant Melanoma
Brief: Ultimovacs Receives Intention To Grant Notice On European Patent
Brief: Ultimovacs Q4 Total Loss Was NOK 70.5 Mln
Brief: Ultimovacs Says Cemiplimab To Replace Pembrolizumab In Trial
Brief: Ultimovacs Q3 Total Loss At NOK 38.3 Mln